A panel of esteemed breast cancer experts discuss the latest research in the treatment of HER2+ metastatic breast cancer with brain metastases and how data updates would affect treatment-decision making in three patient cases.
EP. 1: Case Presentation: A 69-Year-Old Woman with HER2+ Metastatic Breast Cancer (mBC)
Heather McArthur, MD, presents the case of a 69-year-old woman with stage II HER2+ mBC for discussion.
EP. 2: Trastuzumab Deruxtecan Maintenance after First-Line Therapy for HER2+ mBC
Joyce O’Shaughnessy, MD, starts a discussion on maintenance therapy with trastuzumab deruxtecan in patient with HER2+ mBC.
EP. 4: Third-Line Treatment Options for HER2+ mBC after Progression on Trastuzumab Deruxtecan
Heather McArthur, MD, describes what treatment options she would consider in the third-line setting for HER2+ mBC.
EP. 5: Case Presentation: A 60-Year-Old Woman with HER2+ mBC with Brain Metastases
Virginia Kaklamani, MD, presents the case of a 60-year-old patient with stage III HER2+ mBC with brain metastases.
EP. 6: Treatment Approaches in HER2+ mBC with Brain Metastases
The panel reviews the treatment approaches for HER2+ mBC with active brain metastases and the factors to consider during treatment decision-making.
EP. 7: Managing Adverse Events of Tucatinib in Patients with HER2+ mBC with Brain Metastases
Joyce O’Shaughnessy, MD, starts a conversation on managing the adverse events of tucatinib therapy in patients with HER2+ mBC with brain metastases.
EP. 9: Systemic Therapy Before Whole Brain Radiation for HER2+ mBC with Brain Metastases
The panel discusses the systemic therapy options for patients with HER2+ mBC with brain metastases before moving to whole brain radiation therapy.
EP. 10: Case Presentation: A 62-Year-Old Woman with HER2+ mBC with Pulmonary and Brain Metastases
Andrew Brenner, MD, presents the case of a 62-year-old patient with stage II HER2+ mBC presenting with both pulmonary and brain metastases.